Tag - IMRA

Developments

Imara gets EC orphan drug designation for sickle cell disease

Imara’s (NASDAQ:IMRA) IMR-687 received European Commission orphan drug designation for the treatment of sickle cell disease. In a statement, Imara’s president and CEO, Rahul Ballal, said the designation reinforces “the...

August 25, 2020

Developments

Imara doses first patient in Phase 2b sickle cell disease trial

Imara (NASDAQ:IMRA) dosed the first patient in its Phase 2b Ardent trial evaluating IMR-687 for the treatment of sickle cell disease. The trial will enrol some 99 patients with sickle cell disease, who will receive...

August 13, 2020

Developments

Imara granted FDA orphan drug designation for the treatment of beta-thalassemia

The FDA granted Imara’s (NASDAQ:IMRA) IMR-687 orphan drug designation for the treatment of beta-thalassemia. Beta-thalassemia is a blood disorder characterized by reduced levels of hemoglobin. IMR-687 is small molecule...

June 24, 2020

Markets

SVB Leerink starts Imara at OP; PT $25

SVB Leerink initiated coverage of Imara (NASDAQ:IMRA) with an “outperform” rating and $25 price target in 12 months. The stock closed at $15.75 on April 3. Imara is focused on developing and commercializing novel...

April 6, 2020

Tag - IMRA

Imara gets EC orphan drug designation for sickle cell disease

Imara doses first patient in Phase 2b sickle cell disease trial

Imara granted FDA orphan drug designation for the treatment of beta-thalassemia

SVB Leerink starts Imara at OP; PT $25

General

More